



WEBINAR

# TOP TAKEAWAYS

## Perspectives on Precision Partnering

Precision medicine continues to dramatically transform the healthcare landscape by developing and implementing cutting-edge solutions that significantly improve patient outcomes. Through the groundbreaking creation and rapid development of diagnostic tools and treatments for cancer and other conditions, effective partnerships and collaborations have become essential for advancing this new era of patient care and disease prevention.

Moderator Carolyn Metnick, Partner at McDermott Will & Emery, was joined by Leonard Achan, Senior Vice President, Hospital for Special Surgery, Michael Hamilton, Chief Privacy Officer, Invitae, Anushka Sunder, Managing Director, Blackstone and Ingrid Vasiliu-Feltes, M.D., Chief Quality & Innovation Officer, MEDNAX and President, Detect Genomix, for a conversation on the key topics and evolving trends impacting precision health partnerships. Read on for our top takeaways from this program.

1

Precision medicine is the approach of using all of a person's clinical data to guide more informed care and clinical outcomes for that individual. The data could include aspects such as genetics, biometrics and family history.

2

Collaborative efforts related to precision medicine are varied and can involve the contributions of many parties, such as entrepreneurs, provider organizations such as health systems and physician organizations, biopharma partners, and commercial entities.

3

There are several challenges and barriers to the acceptance of precision medicine. These include:

- Limited and defined pathways for how data can be used (*i.e.*, the complex patchwork framework of federal and state privacy and health information laws), and difficulties navigating volumes of data within the complex regulatory environment
- Legal barriers related to the acceptance of precision medicine and other innovative technology such as blockchain and artificial intelligence
- Ethical considerations, such as data access for a wide audience of patients, providers and health systems
- The need to educate patients on the types of data and insights that can be gained
- The lack of reimbursement and widely accepted payment models
- The need to increase the knowledge and awareness of precision medicine, generally, and to modernize existing policies to account for advancements in technologies

Looking ahead, there are several opportunity areas for growth, improvement and development related to precision medicine. These areas include:



- Alignment of key stakeholders to show the value of precision medicine
- Increased understanding of the different stakeholder viewpoints
- Targeted therapies that will increase requests for genetic testing
- Reconciling innovation with privacy laws
- New players entering the space from other industries (e.g., financial companies)
- Increase in consumer base as younger generations are more comfortable with data sharing
- More models of care, more patient access and better payment options.

VISIT [MWE.COM/HEALTH](https://www.mwe.com/health)

©7/14/2021 McDermott Will & Emery. McDermott Will & Emery conducts its practice through separate legal entities in each of the countries where it has offices. For a complete list visit [mwe.com/legalnotices](https://www.mwe.com/legalnotices).

**McDermott  
Will & Emery**